
EquitySector - HealthcareVery High Risk
NAV (20-Mar-26)
Returns (Since Inception)
Fund Size
₹43 Cr
Expense Ratio
0.24%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.30%
+3.55% (Cat Avg.)
3 Years
+25.66%
+24.47% (Cat Avg.)
Since Inception
+18.77%
— (Cat Avg.)
| Equity | ₹42.7 Cr | 99.84% |
| Others | ₹0.07 Cr | 0.16% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹5.76 Cr | 13.46% |
| Divi's Laboratories Ltd | Equity | ₹2.56 Cr | 5.99% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹2.53 Cr | 5.92% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹2.5 Cr | 5.85% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2.46 Cr | 5.75% |
| Cipla Ltd | Equity | ₹2.39 Cr | 5.59% |
| Lupin Ltd | Equity | ₹1.75 Cr | 4.09% |
| Fortis Healthcare Ltd | Equity | ₹1.54 Cr | 3.60% |
| Torrent Pharmaceuticals Ltd | Equity | ₹1.43 Cr | 3.34% |
| Laurus Labs Ltd | Equity | ₹1.31 Cr | 3.06% |
| Aurobindo Pharma Ltd | Equity | ₹1.07 Cr | 2.50% |
| Alkem Laboratories Ltd | Equity | ₹1.04 Cr | 2.42% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹1 Cr | 2.35% |
| Biocon Ltd | Equity | ₹0.87 Cr | 2.04% |
| Mankind Pharma Ltd | Equity | ₹0.79 Cr | 1.84% |
| Zydus Lifesciences Ltd | Equity | ₹0.73 Cr | 1.70% |
| Ipca Laboratories Ltd | Equity | ₹0.67 Cr | 1.57% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.58 Cr | 1.36% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.52 Cr | 1.23% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.48 Cr | 1.12% |
| Gland Pharma Ltd | Equity | ₹0.45 Cr | 1.06% |
| Abbott India Ltd | Equity | ₹0.44 Cr | 1.03% |
| Sai Life Sciences Ltd | Equity | ₹0.43 Cr | 1.00% |
| Ajanta Pharma Ltd | Equity | ₹0.4 Cr | 0.93% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.39 Cr | 0.91% |
| Wockhardt Ltd | Equity | ₹0.35 Cr | 0.83% |
| Acutaas Chemicals Ltd | Equity | ₹0.35 Cr | 0.82% |
| Neuland Laboratories Ltd | Equity | ₹0.35 Cr | 0.81% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.34 Cr | 0.79% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.33 Cr | 0.77% |
| Piramal Pharma Ltd | Equity | ₹0.3 Cr | 0.70% |
| Global Health Ltd | Equity | ₹0.3 Cr | 0.70% |
| Natco Pharma Ltd | Equity | ₹0.28 Cr | 0.65% |
| Granules India Ltd | Equity | ₹0.27 Cr | 0.62% |
| Syngene International Ltd | Equity | ₹0.25 Cr | 0.59% |
| Pfizer Ltd | Equity | ₹0.24 Cr | 0.56% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.23 Cr | 0.53% |
| Jubilant Pharmova Ltd | Equity | ₹0.22 Cr | 0.51% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹0.2 Cr | 0.46% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.19 Cr | 0.43% |
| Strides Pharma Science Ltd | Equity | ₹0.18 Cr | 0.41% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.17 Cr | 0.41% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.17 Cr | 0.41% |
| Indegene Ltd | Equity | ₹0.16 Cr | 0.38% |
| Cohance Lifesciences Ltd | Equity | ₹0.16 Cr | 0.36% |
| Metropolis Healthcare Ltd | Equity | ₹0.15 Cr | 0.36% |
| Poly Medicure Ltd | Equity | ₹0.15 Cr | 0.36% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.15 Cr | 0.36% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.15 Cr | 0.34% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.32% |
| Concord Biotech Ltd | Equity | ₹0.13 Cr | 0.30% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.12 Cr | 0.29% |
| Procter & Gamble Health Ltd | Equity | ₹0.12 Cr | 0.29% |
| Aarti Pharmalabs Ltd | Equity | ₹0.12 Cr | 0.27% |
| Marksans Pharma Ltd | Equity | ₹0.12 Cr | 0.27% |
| Shilpa Medicare Ltd | Equity | ₹0.11 Cr | 0.27% |
| Sanofi India Ltd | Equity | ₹0.11 Cr | 0.26% |
| Caplin Point Laboratories Ltd | Equity | ₹0.11 Cr | 0.25% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.09 Cr | 0.22% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.09 Cr | 0.21% |
| Alivus Life Sciences Ltd | Equity | ₹0.09 Cr | 0.21% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.08 Cr | 0.19% |
| Viyash Scientific Ltd | Equity | ₹0.08 Cr | 0.18% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.08 Cr | 0.18% |
| Net Receivables / (Payables) | Cash | ₹0.07 Cr | 0.16% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.07 Cr | 0.15% |
| Thyrocare Technologies Ltd | Equity | ₹0.06 Cr | 0.13% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.06 Cr | 0.13% |
| FDC Ltd | Equity | ₹0.05 Cr | 0.13% |
| Supriya Lifescience Ltd | Equity | ₹0.05 Cr | 0.12% |
| Morepen Laboratories Ltd | Equity | ₹0.05 Cr | 0.11% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.05 Cr | 0.11% |
| Blue Jet Healthcare Ltd | Equity | ₹0.04 Cr | 0.10% |
| Bliss GVS Pharma Ltd | Equity | ₹0.04 Cr | 0.10% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.04 Cr | 0.10% |
| Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.10% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.04 Cr | 0.10% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.04 Cr | 0.09% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.08% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.04 Cr | 0.08% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.04 Cr | 0.08% |
| Innova Captab Ltd | Equity | ₹0.03 Cr | 0.08% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.03 Cr | 0.07% |
| Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.07% |
| Suven Life Sciences Ltd | Equity | ₹0.03 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.06% |
| RPG Life Sciences Ltd | Equity | ₹0.03 Cr | 0.06% |
| Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.06% |
| Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.05% |
| Hikal Ltd | Equity | ₹0.02 Cr | 0.05% |
| Kwality Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
| Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.05% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.05% |
| Vimta Labs Ltd | Equity | ₹0.02 Cr | 0.05% |
| 3B BlackBio Dx Ltd | Equity | ₹0.02 Cr | 0.05% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.05% |
| Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.02 Cr | 0.04% |
| Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.04% |
| Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.04% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.02 Cr | 0.04% |
| Panacea Biotec Ltd | Equity | ₹0.02 Cr | 0.04% |
| Suraksha Diagnostic Ltd | Equity | ₹0.02 Cr | 0.04% |
| Wanbury Ltd | Equity | ₹0.02 Cr | 0.04% |
| Fischer Medical Ventures Ltd | Equity | ₹0.02 Cr | 0.04% |
| Bajaj Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.03% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.03% |
| Laxmi Dental Ltd | Equity | ₹0.01 Cr | 0.03% |
| Kopran Ltd | Equity | ₹0.01 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
| Fermenta Biotech Ltd | Equity | ₹0.01 Cr | 0.02% |
| Jagsonpal Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.02% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.02% |
| Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.02% |
| Health X Platform Ltd | Equity | ₹0.01 Cr | 0.02% |
| Anuh Pharma Ltd Shs Dematerialised | Equity | ₹0.01 Cr | 0.02% |
| Shree Ganesh Remedies Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.01% |
| Nectar Lifesciences Ltd | Equity | ₹0 Cr | 0.01% |
Large Cap Stocks
45.90%
Mid Cap Stocks
28.57%
Small Cap Stocks
25.38%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹42.31 Cr | 98.92% |
| Basic Materials | ₹0.39 Cr | 0.92% |
Standard Deviation
This fund
16.32%
Cat. avg.
16.02%
Lower the better
Sharpe Ratio
This fund
1.17
Cat. avg.
1.11
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.01
Higher the better
ISIN INF247L01BB1 | Expense Ratio 0.24% | Exit Load - | Fund Size ₹43 Cr | Age 3 years 7 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,42,889 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments